Critical Review of GABA-ergic Drugs in the Treatment of Schizophrenia
The DOI matches its Crossref record.
Abstract
GABA-ergic medications may have a potential role in the treatment of schizophrenia. Laboratory evidence has generally supported the ability of gamma-aminobutyric acid (GABA) to reduce dopaminergic activity and has suggested that GABA may be effective in combating hypofrontality by acting on mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs. Although the results of clinical trials of several GABA-ergic compounds have been inconclusive because of methodologic limitations and drug toxicity, benzodiazepines and valproate seem to be associated with favorable treatment outcomes, especially when combined with typical antipsychotic agents. This study concludes that further investigation of the use of GABA in schizophrenia is likely to improve the understanding of the psychopathology of this illness and to expand our treatment alternatives. Also provided are suggestions to enhance the design of future studies, improve the potential for favorable treatment outcomes, and assist in predicting patients' responses to GABA-ergic medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
“Indeed, GABA-mimetic drugs, such as mood-stabilizing anticonvulsants, show efficacy in the treatment of both schizophrenia (Wassef et al. 1999) and bipolar disorder (Bowden 1998), although patients with affective disorder show a more striking beneficial effect.”
BackgroundGABAA Receptor Channel Pharmacology
Johnston, G. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054021024 · Cited by 274
Pharmacological Management of Acute Agitation
Battaglia, J. (2005) · Drugs · doi:10.2165/00003495-200565090-00003 · Cited by 254
Canetta, S., Bolkan, S., Padilla-Coreano, N., Song, L. J., Sahn, R., Harrison, N. L., Gordon, J. A., Brown, A., & Kellendonk, C. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.222 · Cited by 201
Self-citationSleep and circadian rhythm dysregulation in schizophrenia
Monti, J. M., BaHammam, A. S., Pandi-Perumal, S. R., Bromundt, V., Spence, D. W., Cardinali, D. P., & Brown, G. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.021 · Cited by 157
Metadata
- Authors
- Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W. J., & Rose, R. M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-06
- Volume
- 19
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1979413325
- Cited by
- 68
- References
- 0
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Critical Review of GABA-ergic Drugs in the Treatment of Schizophrenia. https://app.cochat.ai/papers/10.1097/00004714-199906000-00004
- The paper
- Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W. J., & Rose, R. M. (1999). Critical Review of GABA-ergic Drugs in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199906000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.